Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

INTRODUCTION: Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post‐liver transplantation (LT) HCC recurrence remain unclear. We investigated the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Kyunghye, Casadei‐Gardini, Andrea, Yoo, Changhoon, Iavarone, Massimo, Ryu, Min‐Hee, Park, Sook Ryun, Kim, Hyung‐Don, Yoon, Young‐In, Jung, Dong‐Hwan, Park, Gil‐Chun, Ahn, Chul‐Soo, Moon, Deok‐Bog, Hwang, Shin, Kim, Ki‐Hun, Song, Gi‐Won, Mazzarelli, Chiara, Alimenti, Eleonora, Chan, Stephen L., De Giorgio, Massimo, Ryoo, Baek‐Yeol, Lee, Sung‐Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939097/
https://www.ncbi.nlm.nih.gov/pubmed/36812124
http://dx.doi.org/10.1002/cam4.5123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939097/
https://www.ncbi.nlm.nih.gov/pubmed/36812124
http://dx.doi.org/10.1002/cam4.5123

Ejemplares similares